Back to search results

Retatrutide for Obesity, Overweight, and Chronic Low Back Pain

This study is testing a drug called Retatrutide (LY3437943) to see if it can help people with obesity or overweight who also have chronic low back pain. Researchers want to know if Retatrutide is safe and effective in reducing pain and helping with weight loss. You might be able to join if you are 18 or older, have ongoing low back pain that mainly affects your lower back, and have a Body Mass Index (BMI) of 27 or higher. You also need to have tried to lose weight with diet before. The study will measure changes in your pain intensity and body weight over about 72 weeks. The current status of this study is unclear, and it plans to enroll 586 participants.

Study design
This is an interventional study comparing Retatrutide to a placebo (an inactive substance). It plans to enroll 586 participants.
What's involved
Participation in the study will last about 80 weeks. You will receive either Retatrutide or a placebo, administered under the skin (SC).
Compensation
Not stated in the trial record.
Follow-up
Your pain intensity and body weight will be measured up to 72 weeks after the start of the study.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT07035093

A Study of Retatrutide (LY3437943) in Participants Who Have Obesity or Overweight and Chronic Low Back Pain

Active, Not Recruiting
PHASE3Ages 18+InterventionalTreatment
Eli Lilly and Company
~586 participants
Updated 2026-07-23 on ClinicalTrials.gov
What's tested:RetatrutidePlacebo

At a glance

Recruiting sites
0 of 40 listed sites are recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Change from Baseline in Pain Intensity Per Numeric Rating Scale
Measured over Baseline, up to 72 weeks
+1 more outcome measured

Conditions

Obesity
Overweight
Chronic Low Back Pain (CLBP)

Explore related trials

Chronic low back painObesityOverweight

Where it's being run

40 sites across 17 states
Argentina9
Florida6
Canada5
California4
Texas3
Arizona2
Colorado1
Kansas1

Study leadership

  • Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 8 AM - 8 PM Eastern time (UTC/GMT - 5 hours, EST) · STUDY_DIRECTOR · Eli Lilly and Company

Who to contact

This trial hasn't published a contact. View it on ClinicalTrials.gov

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Have a history of axial-predominant low back pain
Have pain that is restricted to the low back or with a referral pattern limited to the proximal legs
Have a body mass index (BMI) ≥27 kilograms per square meter (kg/m2) at screening
Have a history of at least 1 self-reported unsuccessful dietary effort to lose body weight

Exclusion

Have a non-axial origin low back pain
Have had botulinum or steroid injections to the spine within 1 year of screening
Have had trigger point injection to the spine within 6 months of screening
Have a self-reported change in body weight \>5 kilograms (kg) (11 pounds) within 90 days prior to screening
Have been taking drugs to promote body weight reduction, including over-the-counter medications, within 90 days prior to screening
Have a prior or planned surgical treatment for obesity
Have Type 1 Diabetes, Type 2 Diabetes, or any other type of diabetes

What this trial measures

  • Change from Baseline in Pain Intensity Per Numeric Rating ScaleBaseline, up to 72 weeks
  • Percent Change from Baseline in Body WeightBaseline, up to 72 weeks